Notably, the selective JAK1 inhibitor, itacitinib, was discontinued after phase 3 clinical trials due to its ineffectiveness in treatment of GVHD, and there are no current data on the risks of fungal infections with this drug (32). Here, JAK1 is linked to graft versus host disease.